Journey Medical Corp
DERM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001867066
No open-market purchases or sales by Journey Medical Corp insiders were filed in the last 90 days; 71 institutions reported holding it in 13F filings for Q2 2026, worth $75.2M in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Journey Medical Corp as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- +8 vs. Q2 2022
- Shares held
- 1.88M
- +134.2K (+7.7%) vs. Q2 2022
- Total value
- $4.62M
- −$1.90M (−29.2%) vs. Q2 2022
- New holders
- 8
- 4 more added
- Sold out
- 0
- 4 more reduced
1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DERM on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 71 | $75.2M |
| Q1 2026 | 72 | $55.8M |
| Q4 2025 | 77 | $85.0M |
| Q3 2025 | 68 | $61.9M |
| Q2 2025 | 56 | $46.6M |
| Q1 2025 | 38 | $29.6M |
| Q4 2024 | 37 | $14.8M |
| Q3 2024 | 36 | $12.2M |
| Q2 2024 | 35 | $13.3M |
| Q1 2024 | 33 | $6.68M |
| Q4 2023 | 36 | $7.80M |
| Q3 2023 | 21 | $5.85M |
| Q2 2023 | 20 | $2.63M |
| Q1 2023 | 17 | $2.62M |
| Q4 2022 | 18 | $5.13M |
| Q3 2022 | 20 | $4.62M |
| Q2 2022 | 13 | $6.52M |
| Q1 2022 | 14 | $7.94M |
| Q4 2021 | 14 | $8.76M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Journey Medical Corp; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| B. Riley Financial, Inc. | 864,695 | $2.13M | 0.38% | 00.0% | Unchanged |
| Opaleye Management Inc. | 259,293 | $638.0K | 0.26% | +13,560+5.5% | Added |
| Perkins Capital Management Inc | 208,950 | $514.0K | 0.58% | −11,100−5.0% | Reduced |
| American Financial Group Inc | 180,000 | $443.0K | 0.15% | 00.0% | Unchanged |
| Neuberger Berman Group LLC | 161,707 | $398.0K | 0.00% | −35,430−18.0% | Reduced |
| First Manhattan Co | 35,294 | $86.0K | 0.00% | +35,294 | New |
| Geode Capital Management, LLC | 27,555 | $67.0K | 0.00% | +27,555 | New |
| Cerity Partners LLC | 25,421 | $63.0K | 0.00% | +25,421 | New |
| Susquehanna International Group, LLP | 22,094 | $54.0K | 0.00% | +22,094 | New |
| Wealth Alliance Advisory Group, LLC | 21,500 | $53.0K | 0.02% | +21,500 | New |
| National Asset Management, Inc. | 17,250 | $43.0K | 0.00% | +17,250 | New |
| Vanguard Group Inc | 16,843 | $41.0K | 0.00% | +6,408+61.4% | Added |
| Creative Planning | 11,764 | $29.0K | 0.00% | 00.0% | Unchanged |
| Buckingham Strategic Partners | 10,000 | $25.0K | 0.00% | +10,000 | New |
| BlackRock Inc. | 8,258 | $21.0K | 0.00% | −235−2.8% | Reduced |
| Tower Research Capital LLC (TRC) | 5,056 | $12.0K | 0.00% | +3,021+148.5% | Added |
| UBS Group AG | 1,444 | $4.00K | 0.00% | −1,245−46.3% | Reduced |
| Essex Investment Management Co LLC | 1,400 | $3.00K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 43 | $0 | 0.00% | +14+48.3% | Added |
| Royal Bank of Canada | 47 | $0 | 0.00% | +47 | New |
| B. Riley Wealth Management, Inc. | – | – | – | – | Not filed |